Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several safety/adverse-event statements align with the provided label excerpts, but multiple efficacy/indication and dosing-frequency claims are not supported by the supplied labeling text. Several claims are broader than the label’s evaluated indication (symptomatic atrial fibrillation recurrence in patients without structural heart disease) and include specifics (dose frequency, IR vs ER interchangeability) not substantiated by the provided excerpts.
Category Scores
Accurate Statements
Propafenone is an antiarrhythmic medicine (used to control rhythm problems / abnormal heart rhythms).
Supported generally by the label describing propafenone as a Class 1C antiarrhythmic with electrophysiologic effects and its indication for symptomatic atrial fibrillation recurrence prolongation (Sections: INDICATIONS AND USAGE; CLINICAL PHARMACOLOGY).
Common side effects reported for propafenone include dizziness, nausea, taste disturbance, and headache.
Supported for dizziness, nausea, and taste disturbance; headache is not listed in the provided adverse-event sentence (most commonly reported adverse events) but other adverse events may exist in the full label not provided. Dizziness/nausea/taste disturbance are explicitly listed (Section: ADVERSE REACTIONS).
Serious effects can occur with antiarrhythmic medicines using propafenone, including new or worsened arrhythmias.
Supported: proarrhythmic effects including new or worsened arrhythmias (Section: WARNINGS - Proarrhythmic Effects).
Serious effects with propafenone can include changes in heart rate and blood pressure.
Partially supported: label excerpts describe proarrhythmia and QRS/QT/conduction effects; explicit mention of heart rate and blood pressure changes is not provided in the excerpts. (Sections: WARNINGS - Proarrhythmic Effects; CLINICAL PHARMACOLOGY - conduction/QRS/QT considerations).
Anyone experiencing chest pain, fainting, severe dizziness, or sudden shortness of breath while on antiarrhythmic medicines should seek urgent medical care.
Not directly supported by the provided label excerpts (no patient-advice language or specific symptom list provided in the excerpts). (Section: PRECAUTIONS does include patient instruction about electrolytes/dosing missed dose, but not this urgent-care symptom list.)
Propafenone has important drug-interaction considerations.
Supported: label contains metabolism information and specific interactions with CYP inhibitors and other drugs (Section: DRUG INTERACTIONS).
Different propafenone ER products can have different strengths and dosing instructions.
Partially supported: the dosing scheme is individualized and available ER strengths are referenced by dose titration (225 mg, 325 mg, 425 mg every 12 hours). The claim about “different products” having different instructions is not explicitly stated in the provided excerpts. (Section: DOSAGE AND ADMINISTRATION; may vary by full prescribing product).
Unsupported Statements
“ER” in propafenone ER stands for extended release.
No explicit label text excerpt provided defining “ER” as extended release (Sections reviewed do not include that definition).
Propafenone ER is formulated to release more slowly over time.
No explicit label excerpt provided describing the formulation mechanism of extended release (only the dosage form name “extended-release” is implied).
Propafenone ER can be taken less often than immediate-release propafenone.
No provided excerpt compares dosing frequency between ER and immediate-release products.
Propafenone is used to control some forms of supraventricular arrhythmias.
The provided label indication is specifically for prolonging time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease; no generalized claim about supraventricular arrhythmias is explicitly supported.
Propafenone is used to control some forms of ventricular arrhythmias.
The provided label excerpt does not indicate ventricular arrhythmia treatment; it instead discusses avoiding antiarrhythmics in non-life-threatening ventricular arrhythmias and contains proarrhythmic warnings.
Propafenone ER is typically taken once or twice daily.
The provided dosage instructions specify dosing every twelve hours (BID) for ER titration; “once daily” is not supported by the provided excerpts.
The exact dosing of propafenone ER depends on the specific product strength and the prescriber’s instructions.
The label states dose must be individually titrated based on response/tolerance and provides titration steps (225 mg q12h, etc.). It does not state dependence on “specific product strength” as the key basis, though strength is part of the titration. This is partially supported at best; as written it is not explicitly supported.
Extended-release tablets of propafenone ER should not be crushed or split unless the prescription label or pharmacist specifically says it’s allowed.
No provided label excerpt addresses crushing/splitting instructions for ER capsules/tablets.
Anyone experiencing chest pain, fainting, severe dizziness, or sudden shortness of breath while on antiarrhythmic medicines should seek urgent medical care.
No such patient-symptom urgent care instruction is present in the provided excerpts.
The risk with propafenone is higher in people with certain conduction problems.
Conduction defects are addressed as contraindications and first-degree AV block/conduction effects are described, but the excerpt does not explicitly quantify or state that “risk is higher” in “certain conduction problems” beyond contraindication language.
The risk with propafenone is higher in people with other conditions that make rhythm-control drugs unsafe.
The label excerpt supports caution/avoidance in structural heart disease and CHF scenarios, but not the generalized phrasing about “other conditions that make rhythm-control drugs unsafe.”
Immediate-release propafenone is dosed differently than propafenone ER.
No ER vs immediate-release dosing comparison is included in the provided excerpts.
Propafenone ER and immediate-release propafenone are not automatically interchangeable.
No provided excerpt states interchangeability guidance between ER and immediate-release.
Contradictions
Low
AI Statement
Propafenone is used to control some forms of ventricular arrhythmias.
Label Reference
Label excerpts provided indicate avoidance of antiarrhythmics in non-life-threatening ventricular arrhythmias and contain proarrhythmic warnings; no ventricular arrhythmia indication is provided. Direct contradiction not explicitly shown as “contraindicated for ventricular arrhythmias” in the excerpts, but the statement is inconsistent with the provided indication scope.
Important Omissions
The label indication is specifically for prolonging the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease, with explicit limitations regarding permanent atrial fibrillation, atrial flutter/PSVT, and not for ventricular rate control.
Importance:
Moderate
Key contraindications (e.g., conduction/impulse disorders without pacemaker, CHF/cardiogenic shock, electrolyte imbalance, etc.) are not addressed in the AI claims set provided.
Importance:
Moderate
Specific boxed warning context (CAST increased death/reversed cardiac arrest rates with Class 1C drugs like encainide/flecainide) and ECG evaluation prior to and during therapy are not reflected in the AI statements beyond general “serious effects.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety concepts are included (proarrhythmia/new or worsened arrhythmias, need for ECG evaluation is not mentioned; urgent care symptom list is not label-supported; indication is broadened beyond the specific label (symptomatic atrial fibrillation recurrence without structural heart disease). Dosing-frequency claims include unsupported “once daily,” which could affect safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Indication overgeneralization and unsupported dosing/frequency and ER-vs-IR interchangeability guidance not supported by the provided label excerpts.
Suggested Improvement
Constrain efficacy/indication statements to “prolong time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease” and the label’s stated limitations (not evaluated for permanent AF and not for ventricular rate control). Replace “typically once or twice daily” with the label’s ER dosing interval (every 12 hours) and remove ER definition/crushing/interchangeability claims unless explicitly supported by the prescribing information.